Carolina Ofir Jaliffa

Dr. Carolina Ofir Jaliffa

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2005 in Experimental Eye Research
Verified
Journal Article
Closed access
MMMaría Cecilia Moreno
María Cecilia Moreno
HMHernán J. Aldana Marcos
Hernán J. Aldana Marcos
JCJ. Oscar Croxatto
J. Oscar Croxatto
PSPablo H. Sande
Pablo H. Sande
JCJulieta Campanelli
Julieta Campanelli
RRRuth E. Rosenstein
Ruth E. Rosenstein

1 August 2009 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
CJCarolina Ofir Jaliffa
Carolina Ofir Jaliffa
IAIlhame Ameqrane
Ilhame Ameqrane
ADAnouk Dansault
Anouk Dansault
JLJulia Leemput
Julia Leemput
VVVe´rOnique Vieira
Ve´rOnique Vieira
MAMarc Abitbol
Marc Abitbol
Purpose. Sirtuin1 (Sirt1) is an NAD+-dependent deacetylase involved in development, cell survival, stress resistance, energy metabolism, and aging. It is expressed in the mammalian central nervous system (CNS) and is activated during processes associated with neuroprotection. The retinal degeneration 10 (rd10) mouse model of retinitis pigmentosa (RP) was used to investigate the possible role of Sirt1 in this type of retinal degeneration.

28 August 2001 in Brain Research
Verified
Journal Article
Closed access
CJCarolina Ofir Jaliffa
Carolina Ofir Jaliffa
DSDaniel Saenz
Daniel Saenz
ERErnesto Resnik
Ernesto Resnik
MSMarı́a I Keller Sarmiento
Marı́a I Keller Sarmiento
RRRuth E. Rosenstein
Ruth E. Rosenstein

2 April 2007
Verified
Journal Article
Open access
ADAnouk Dansault
Anouk Dansault
GDGabriel David
Gabriel David
CSClaire Schwartz
Claire Schwartz
CJCarolina Ofir Jaliffa
Carolina Ofir Jaliffa
VVVéronique Vieira
Véronique Vieira
MAMarc Abitbol
Marc Abitbol
The PAX6 gene was first described as a candidate for human aniridia. However, PAX6 expression is not restricted to the eye and it appears to be crucial for brain development. We studied PAX6 mutations in a large spectrum of patients who presented with aniridia phenotypes, Peters' anomaly, and anterior segment malformations associated or not with neurological anomalies. Patients and related families were ophthalmologically phenotyped, and in some cases neurologically and endocrinologically examined. We screened the PAX6 gene by direct sequencing in three groups of patients: those affected by aniridia; those with diverse ocular manifestations; and those with Peters' anomaly. Two mutations were investigated by generating crystallographic representations of the amino acid changes. Three novel heterozygous mutations affecting three unrelated families were identified: the g.572T>C nucleotide change, located in exon 5, and corresponding to the Leucine 46 Proline amino-acid mutation (L46P); the g.655A>G nucleotide change, located in exon 6, and corresponding to the Serine 74 Glycine amino-acid mutation (S74G); and the nucleotide deletion 579delG del, located in exon 6, which induces a frameshift mutation leading to a stop codon (V48fsX53). The L46P mutation was identified in affected patients presenting bilateral microphthalmia, cataracts, and nystagmus. The S74G mutation was found in a large family that had congenital ocular abnormalities, diverse neurological manifestations, and variable cognitive impairments. The 579delG deletion (V48fsX53) caused in the affected members of the same family bilateral aniridia associated with congenital cataract, foveal hypolasia, and nystagmus. We also detected a novel intronic nucleotide change, IVS2+9G>A (very likely a mutation) in an apparently isolated patient affected by a complex ocular phenotype, characterized primarily by a bilateral microphthalmia. Whether this nucleotide change is indeed pathogenic remains to be demonstrated. Two previously known heterozygous mutations of the PAX6 gene sequence were also detected in patients affected by aniridia: a de novo previously known nucleotide change, g.972C>T (Q179X), in exon 8, leading to a stop codon and a heterozygous g.555C>A (C40X) recurrent nonsense mutation in exon 5. No mutations were found in patients with Peters' anomaly. We identified three mutations associated with aniridia phenotypes (Q179X, C40X, and V48fsX53). The three other mutations reported here cause non-aniridia ocular phenotypes associated in some cases with neurological anomalies. The IVS2+9G>A nucleotide change was detected in a patient with a microphthalmia phenotype. The L46P mutation was detected in a family with microphthalmia, cataract, and nystagmus. This mutation is located in the DNA-binding paired-domain and the crystallographic representations of this mutation show that this mutation may affect the helix-turn-helix motif, and as a consequence the DNA-binding properties of the resulting mutated protein. Ser74 is located in the PAX6 PD linker region, essential for DNA recognition and DNA binding, and the side chain of the Ser74 contributes to DNA recognition by the linker domain through direct contacts. Crystallographic representations show that the S74G mutation results in no side chain and therefore perturbs the DNA-binding properties of PAX6. This study highlights the severity and diversity of the consequences of PAX6 mutations that appeared to result from the complexity of the PAX6 gene structure, and the numerous possibilities for DNA binding. This study emphasizes the fact that neurodevelopmental abnormalities may be caused by PAX6 mutations. The neuro-developmental abnormalities caused by PAX6 mutations are probably still overlooked in the current clinical examinations performed throughout the world in patients affected by PAX6 mutations.

1 February 2003 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
AVAdriana S Veleiro
Adriana S Veleiro
RRRuth E Rosenstein
Ruth E Rosenstein
CJCarolina Ofir Jaliffa
Carolina Ofir Jaliffa
MGMarı́a L Grilli
Marı́a L Grilli
FSFlorencia Speroni
Florencia Speroni
GBGerardo Burton
Gerardo Burton

1 March 2008 in Neurochemistry International
Verified
Journal Article
Closed access
MMMaría Cecilia Moreno
María Cecilia Moreno
NZNuria de Zavalía
Nuria de Zavalía
PSPablo Sande
Pablo Sande
CJCarolina Ofir Jaliffa
Carolina Ofir Jaliffa
DFDiego C. Fernandez
Diego C. Fernandez
RRRuth E. Rosenstein
Ruth E. Rosenstein